FCGR3A and COVID-19: As key findings we identify de novo produced afucosylated SARS-CoV-2 IgG and the emergence of soluble circulating immune complexes (sICs) activating FcγRIIIA/CD16A as potential risk factors closely associated to COVID-19 severity.